Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)
IO Biotech’s melanoma vaccine Cylembia plus Merck’s Keytruda missed statistical significance in Phase 3, with median progression-free survival of 19.4 months versus 11 months for Keytruda alone. The FDA approved PharmaTher’s ketamine (KETARx) for anesthesia and pain. A dengue outbreak in Pacific Island nations has infected over 16,500 and killed 17 in 2025, with Fiji, Samoa, and Tonga hardest hit.